Patent US2725823A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4140767A Expired / Lapsed US ⏱️ 0.0 years remaining

Somatostatin analogs

Assignee: Merck and Co Inc
•
Filing: 1977-12-01
•
Granted: 1979-02-20
•
Expires: 1997-12-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract {PG,1 Bicyclic somatostatin analogs and pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by the solid phase method. These analogs have the property of inhibiting the release of growth hormone without affecting the level of gastric secretions or without affecting the level of gastric secretions, insulin and glucagon in humans and animals. The compounds are particularly useful in the treatment of acromegaly and diabetic retinopathy. Due to the bicyclic structure, these analogs are resistant to enzymatic metabolism and have a longer duration of activity than somatostatin.

Inventors

  • 👤 Daniel F. Veber

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 11:13
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/655; C07K14/6555; A; A61; A61P; A61P43/00; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/16

Claims Analysis

Total Claims: 6
Claim 1
Independent Claim 5 words
The compounds having the formula:
Claim 2
Dependent Claim 5 words
The compounds having the formula:
Claim 3
Dependent Claim 6 words
The compounds having the formula: ##STR22##
Claim 4
Dependent Claim 6 words
The compounds having the formula: ##STR22##
Claim 5
Dependent Claim 30 words
A pharmaceutical composition comprising a therapeutically effective amount of the peptide having the structure: ##STR23## and non-toxic acid addition salts thereof in a pharmaceutically acceptable liquid or solid carrier thereof.
Claim 6
Dependent Claim 30 words
A pharmaceutical composition comprising a therapeutically effective amount of the peptide having the structure: ##STR23## and non-toxic acid addition salts thereof in a pharmaceutically acceptable liquid or solid carrier thereof.

References Cited (Backward Citations)

US3997517A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-02-19 1982-08-21 1983-02-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-02-19 1986-08-21 1987-02-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-02-19 1990-08-21 1991-02-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag